UNITY Biotechnology Inc
Change company Symbol lookup
Select an option...
UBX UNITY Biotechnology Inc
CVE Cenovus Energy Inc
DIDIY DiDi Global Inc
PPBT Purple Biotech Ltd
PRE Prenetics Global Ltd
APTV Aptiv PLC
$NQUSB60101015LMCAD Nasdaq US Offshore Drilling and Othe
CUTR Cutera Inc
FRD Friedman Industries Inc
PRPRF Prairie Provident Resources Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Unity Biotechnology, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The Company is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The Company's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.

Price
Delayed
$0.405
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 82,493 shares is on pace to be much lighter than UBX's 10-day average volume of 1,194,006 shares.

82,493

UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

5:46 pm ET August 11, 2022 (Globe Newswire) Print

UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325 on Friday, August 12, 2022 at 5:00 a.m. ET/8:00 a.m. ET, with retinal expert Robert Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, UCSF.

The live webcast can be accessed in the "Investors and Media" section of our website, www.unitybiotechnology.com, under "Events & Presentations" or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the "Investors & Media" section of our website, under "Events and Presentations."

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact:

Evoke Canale

Katherine Smith

Katherine.Smith@evokegroup.com

Investor Contact:

Joyce Allaire

LifeSci Advisors

212-915-2569

jallaire@lifesciadvisors.com

Source: Unity Biotechnology, Inc

https://ml.globenewswire.com/media/4a121eed-5811-436f-a241-7b78803ced85/small/unity-color-transp-bg-jpg.png

https://ml.globenewswire.com/media/4a121eed-5811-436f-a241-7b78803ced85/small/unity-color-transp-bg-jpg.png

comtex tracking

COMTEX_412102747/2010/2022-08-11T17:46:02

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.